Adaptive Biotechnologies translates scale and precision of the adaptive immune system into products to diagnose and treat disease.
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.It was founded in 2009 and headquartered in Seattle, Washington.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 12, 2022 | Post-IPO Debt | $125M | 1 | OrbiMed | — | Detail |
Mar 24, 2022 | Post-IPO Equity | — | 1 | ARK Investment Management | — | Detail |
Jul 14, 2020 | Post-IPO Equity | — | — | — | — | Detail |
Jun 26, 2019 | IPO | $300M | — | — | — | Detail |
Mar 5, 2018 | Secondary Market | — | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 28, 2021
Entropy
|
Pre-seed | $1.95M | Blockchain | — |
Oct 19, 2021
Element Finance
|
Series A | $32M | Blockchain | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
OrbiMed | Yes | Post-IPO Debt |
ARK Investment Management | Yes | Post-IPO Equity |
Matrix Capital Management | Yes | Series F |
Viking Global Investors | Yes | Series D |
EquityZen | — | Secondary Market |
Rock Springs Capital | — | Series F |
Senator Investment Group | — | Series F |
Tiger Management Corporation | — | Series F |